Home › Funds › ARCH Venture Management, LLC › LYEL
ARCH Venture Management, LLC position in LYEL
LYELL IMMUNOPHARMA INC · Health Care
ARCH Venture Management, LLC reported holding 3,247,162 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$45.5M, representing 4.14% of its reported portfolio and ranking #8 among its reported holdings. ARCH Venture Management, LLC has disclosed LYEL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARCH Venture Management, LLC's LYEL position evolved
ARCH Venture Management, LLC first disclosed a stake in LYEL in Q2 2025 at 1,820,634 shares (US$16.1M). The position peaked in Q4 2025 at 2,759,072 shares, worth US$84.9M. Across 5 filings, ARCH Venture Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,247,162 shares valued at US$45.5M. Notable position changes include a 52% increase in Q3 2025 (shares rose 90% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.82M | $16.11M | New |
| Q3 2025 | 2.76M | $44.81M | Add |
| Q4 2025 | 2.76M | $84.92M | Hold |
| Q1 2026 | 3.25M | $65.14M | Add |
| Q2 2026 | 3.25M | $45.53M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LYEL and 13F data
LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LYEL
- GSK plc 1.51M sh · $21.25M · Q2 2026
- Orland Properties Ltd 754.70K sh · $10.60M · Q2 2026
- Decheng Capital LLC 692.05K sh · $9.72M · Q2 2026
- Almitas Capital LLC 581.41K sh · $8.17M · Q2 2026
- Foresite Capital Management V, LLC 476.39K sh · $6.69M · Q2 2026
- Opaleye Management Inc. 344.02K sh · $4.83M · Q2 2026
- venBio Partners LLC 337.70K sh · $4.74M · Q2 2026
- Alphabet Inc. 293.26K sh · $4.12M · Q2 2026
- HSG Holding Ltd 152.30K sh · $2.14M · Q2 2026
- Velan Capital Investment Management LP 105.00K sh · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K sh · $1.22M · Q2 2026
More on ARCH Venture Management, LLC
FAQ
How long has ARCH Venture Management, LLC held LYEL?
ARCH Venture Management, LLC has disclosed LYEL holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is ARCH Venture Management, LLC's current position in LYEL?
As of Q2 2026, ARCH Venture Management, LLC holds 3.25M shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $45.53M, representing 4.14% of its reported portfolio and ranking #8.
Has ARCH Venture Management, LLC been buying or selling LYEL?
In the latest 13F filing (Q2 2026), ARCH Venture Management, LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 2.76M shares.
Which other funds hold LYEL?
Other major institutional holders of LYEL include GSK plc, Orland Properties Ltd, Decheng Capital LLC, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.